Peptide market reaches $50-60 billion as GLP-1 drugs dominate growth

The Peptide Alliance says the global peptide market has grown to $50-60 billion, with about $40 billion now tied to GLP-1 drugs like semaglutide and tirzepatide. The new report also tracks a fast-shifting market marked by falling compounded-semaglutide demand, rising clinical trials and new rankings of influencers and conferences.

Why it matters: - The peptide market is now estimated at $50-60 billion, and GLP-1 drugs account for roughly $40 billion of that total. - The size of the GLP-1 segment shows how quickly obesity and metabolic treatments are reshaping demand across clinics, pharmacies, brands and manufacturers. - The report argues that better verified data matters because a fast-growing market can leave patients and clinicians exposed to confusion and low-quality information.

What happened: - The Peptide Alliance released The State of Peptides 2026 (H1 Edition) on July 22, 2026. - The Vancouver-based directory said the report covers the worldwide peptide market and is built on its verified directory of 306 active suppliers. - The report estimates that semaglutide and tirzepatide are driving most of the GLP-1 market growth. - The Peptide Alliance also published ranked indexes of Top Peptide Influencers and Top Peptide Conferences.

The details: - The report says about 1 in 8 U.S. adults has used a GLP-1 medication. - The report says the compounded-semaglutide market fell about 90% year over year after regulatory changes. - The report says retatrutide advanced through Phase 3 and has shown roughly 24.2% mean body-weight reduction in trials. - The Top Peptide Influencers ranking covers voices in media, clinical medicine and research. - The Top Peptide Conferences ranking is led by TIDES USA, the A4M/MMI Annual World Congress and the Peptide World Congress. - The rankings use a published, weighted methodology tied to the same verified supplier directory behind the report. - The directory includes clinics, compounding pharmacies, brands, research labs and manufacturers. - The full report is available free at the State of Peptides report, and no registration is required.

Between the lines: - The report suggests the peptide sector is consolidating around legitimacy after a period of rapid growth and uneven information quality. - The sharp drop in compounded semaglutide points to how regulation can quickly redirect parts of the market. - The new rankings give the Peptide Alliance a way to shape industry visibility, not just catalog suppliers.

What's next: - The Peptide Alliance said it will continue publishing the biannual State of Peptides report. - The organization also said it will maintain its ranked indexes of peptides, influencers and conferences. - Future reports will likely track how GLP-1 demand, regulation and late-stage candidates continue to change the market.

The bottom line: - GLP-1 drugs have become the center of gravity in peptides, and the market's next phase appears to be about regulation, credibility and who controls the information flow.